Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist

Inclusion Criteria: * Acute intracerebral hemorrhage (symptom onset \<12h) * Prior treatment with a novel direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban; last intake \<48hours or proven NOAC activity by relevant coagulation assays) * Age \>18 years, No upper age limit * Informed consent has been received in accordance to local ethics committee requirements Exclusion Criteria: * Severe pre-morbid disability (modified Rankin scale \>4) * Anticoagulation with Vitamin K antagonists (VKA) (recent intake) * Secondary intracerebral hemorrhage (e.g. arteriovenous malformation (AVM), tumor, trauma) Note it is not necessary for investigators to exclude underlying structural abnormality prior to enrolment, but where an underlying structural abnormality is already known, these patients should not be recruited. * Glasgow coma scale \<5 * pregnancy * Planned neurosurgical hematoma evacuation within 24 hours (before follow-up imaging) * Pulmonary embolism/deep vein thrombosis within the last 2 weeks.